ANXA3

Across TCGA pan-cancer cohorts, ANXA3 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated ANXA3 data layer compared with 5 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ANXA3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANXA3 expression acts as an unfavorable survival marker, although some lineages such as COAD and LIHC show a favorable association.

HNSC, COAD, and PAAD are the cancer types where ANXA3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.540	0.720	.005	89	view →
COAD	OS	Tertile	All	0.794	0.578	.001	65	view →
PAAD	DFS	Median	All	0.398	0.575	<.001	60	view →
CESC	DFS	Tertile	All	0.654	0.828	.001	50	view →
LIHC	DFS	Median	III,IV	0.568	0.233	<.001	25	view →
KICH	DFS	Tertile	III,IV	1.000	0.282	.033	23	view →
OV	OS	Quartile	All	0.769	0.646	.022	18	view →
PRAD	DFS	Quartile	All	0.968	0.905	.007	18	view →
SCLC	DFS	Median	IV	0.137	0.559	.008	15	view →
KIRC	DFS	Tertile	All	0.686	0.544	.013	14	view →
ACC	DFS	Median	IV	0.108	0.453	.019	12	view →
SARC	DFS	Quartile	All	0.589	0.397	.010	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

ANXA3–HNSC (DFS)

Open the HNSC breakdown →